Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Oramed Announces $6.5 Million Milestone Payment from HTIT

JERUSALEM, June 21, 2016 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million milestone payment from the previously-announced license and investment agreement between Oramed and HTIT.  The payment follows Oramed’s positive top-line results […]

Read More »

With diabetes, losing weight lowers heart risks, even if you regain it

(Reuters Health) – A large weight loss, even if regained, may help overweight people with type 2 diabetes improve their blood sugar control and cholesterol and lower high blood pressure long-term, a new study suggests. Over four years, even those who regained all of a large weight loss had greater improvements in blood sugar than […]

Read More »

Jardiance slows diabetics’ kidney disease progression

Eli Lilly and Co’s Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial.

Read More »

Sanofi says LixiLan diabetes drug trials meet targets

France’s Sanofi said two late-stage Phase III clinical trials of its LixiLan diabetes drug had met their targets, readying it for approval in the United States in August and Europe in early 2017.

Read More »

Payer Access Special Feature: Different diagnosis

To reach payer audiences, companies have to focus far less on promotional tactics and show the value of their products.

Read More »

U.S. panel backs approval of Sanofi combination diabetes drug

A U.S. advisory panel recommended approval of a new diabetes drug made by Sanofi SA.

Read More »

FDA panel recommends approval of Novo Nordisk diabetes drug

A U.S. advisory panel recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combo.

Read More »

Eli Lilly Projects 20 New Product Launches in 10 Years

Indianapolis-based Eli Lilly and Company is on a roll, announcing that between 2014 and 2023, it may launch 20 new products.

Read More »

FDA staff question utility of Sanofi diabetes drugs

A preliminary FDA review questioned whether Sanofi’s diabetes drug lixisenatide contributed any benefit to a fixed-dose combo product the company hopes to market.

Read More »

Lilly Stops Development of Transition Therapeutics’ Diabetes Drug

Eli Lilly has opted to not advance a diabetes drug into a Phase III clinical trial it was developing in coordination with Canada-based Transition Therapeutics Inc.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom